What You Should Know:
– Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has announced a collaboration with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH).
– The partnership will focus on exploring innovative applications of AI in cancer research, with the goal of improving personalized cancer care.
Focus on Tumor Microenvironment and Immune Phenotyping:
The collaboration will concentrate on advancing research into the tumor microenvironment and immune phenotyping. By analyzing NCI data, the partners aim to uncover insights that can drive more personalized and effective cancer treatment strategies.
Lunit’s AI Tools for NCI Research:
Under the agreement, Lunit’s AI tools will be made available to NCI Center for Cancer Research (CCR) investigators for use across NCI CCR’s portfolio of clinical trials. Lunit will analyze whole-slide images from NCI’s clinical studies using its AI-powered biomarker technologies, specifically Lunit SCOPE® IO and Lunit SCOPE universal IHC. This widespread implementation aims to establish image-analysis AI as a fundamental component of cancer research practice.
Joint Publications and Research Goals:
Lunit and NCI plan to collaborate on the preparation of publications, presentations, and reports to disseminate their findings. The overarching objective of this partnership is to generate data-driven insights that will enable the personalization of treatment approaches for cancer patients.
“This collaboration with the NCI is a testament to the power and potential of Lunit’s AI-driven solutions in advancing the frontier of cancer research,” said Brandon Suh, CEO of Lunit. “By applying our technologies across NCI’s unparalleled research expertise and clinical data, we aim to uncover meaningful insights that can transform cancer treatment and deliver more personalized care to patients worldwide. We are honored to work with one of the world’s leading cancer research institutions to tackle some of the toughest challenges in oncology.”
